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Trastuzumab is used to treat HER2-positive breast cancer; erythropoietin (EPO) is used to alleviate chemo-
therapy-associated side effects. In this issue of Cancer Cell, Liang et al. show that many breast tumors
express EPO receptor (EpoR), whose activation by EPO recovers signaling pathways downregulated by tras-
tuzumab, thereby blunting trastuzumab’s therapeutic effect.Chemotherapeutic agents possessing
different mechanisms of action used in
combination are more effective than
single agents for treatment of cancer
patients. Insights into molecular alter-
ations in cancer cells have led to an
enhanced understanding of cancer eti-
ology and to the development of drugs
targeting the causal components. The
prediction of optimal drug combina-
tions, however, continues to be difficult
and is often based on empirical clini-
cal evidence. Genetic and biochemical
approaches have revealed the most
important genes and proteins in the trans-
formation process and how these com-
ponents interact in organized pathways.
Sequence analyses of cancer genomes
have been correlated with epidemio-
logic and clinical observations to assign
‘‘driver’’ or ‘‘passenger’’ characteristics
to individual mutations (Bozic et al.,
2010). Activated signaling pathways and
expression of particular signaling proteins
have become important indicators for
treatment choice and for therapeutic
success.
HER2 is a certified cancer ‘‘driver’’;
HER2 overexpression due to gene ampli-
fication is observed in 20%–30% of
breast cancers. Patients with tumors
overexpressing HER2 have a worse clin-
ical prognosis and shorter time to relapse
(reviewed in Hynes and Lane, 2005).
The development of trastuzumab, a re-
combinant monoclonal antibody directed
againstHER2, is considered amilestone in
targeted anticancer agents. For patients
with early stage, HER2-positive breast
cancer, trastuzumab treatment in combi-
nation with chemotherapy has shown
significant clinical benefits (Smith et al.,2007); however, not all patients with the
genetic lesion respond. In HER2-positive
breast cancer, the receptor is heavily
phosphorylated and many signaling path-
ways are constitutively active. The mech-
anisms underlying the clinical activity
of trastuzumab are still not completely
understood, and are likely to be multiple.
There is an emerging consensus, how-
ever, that downregulation of the PI3K/
Akt pathway contributes to trastuzumab
response. Indeed, HER2-positive breast
cancer cell lines with PIK3CA mutations
are insensitive to trastuzumab treatment
(Junttila et al., 2009). Moreover, patients
whose tumors have low PTEN levels or
activating PIK3CA mutations tend to
have a lower response to trastuzumab
(Nagata et al., 2004; Berns et al., 2007).
Taken together, trastuzumab resistance
might result when tumor cells are able
to circumvent trastuzumab’s activity on
pathways downstream of HER2.
Erythropoietin (EPO) is frequently used
to alleviate anemia, a complication aris-
ing from chemotherapy and/or from the
release of cytokines by cancer cells.
Anemia is a cause of morbidity and
might also contribute to patient mortality
(reviewed in Rizzo et al., 2010). EPO is
a cytokine that stimulates erythropoiesis
by activating EpoR, its specific cell
surface receptor that has been identified
on erythroid precursor cells. The Jak2
tyrosine kinase associates with EpoR
and EPO binding activates Jak2, thereby
stimulating PI3K/Akt and Erk pathways,
as well as NF-kB and Stat5 activation
(Elliott et al., 2008). As a result, there is
proliferation and terminal differentiation
of erythroid colony forming units (CFUe)
in the bone marrow (Figure 1). Recombi-Cancer Cell 18, Nnant human erythropoietin (rHuEPO) has
replaced blood transfusions and has had
important benefits for cancer patients.
However, detrimental effects elicited by
rHuEPO have become a point of discus-
sion and concern. In addition to the risks
of venous thrombosis following rHuEPO
treatment, there is a concern that EpoR,
which is expressed on many tumors,
might respond to its ligand, leading to
enhanced tumor proliferation or survival
(Rizzo et al., 2010).
Liang et al. (2010) have directly ad-
dressed some of these problems in the
context of HER2-positive breast can-
cer and trastuzumab treatment. Initially,
they used a specific antibody on primary
breast tumors and found that EpoR is
expressed at some level in approximately
80% of the tumors; there was no correla-
tion with HER2 positivity or negativity.
Thus, the majority of HER2-positive can-
cers also express EpoR. Next, in vitro
studies carried out with HER2-positive,
EpoR-expressing breast cancer cell
lines showed that the receptor is func-
tional and that rHuEPO treatment stimu-
lates PI3K/Akt and Erk pathways, and in
some cases, Stat5. As mentioned previ-
ously, treatment of HER2-positive tumor
cells with trastuzumab blocks PI3K/Akt
and Erk pathway activity. However, the
concurrent exposure of HER2-positive,
EpoR-positive models to rHuEPO and
trastuzumab counteracted the inhibitory
effects of trastuzumab on these path-
ways. Moreover, long-term exposure of
these cells to rHuEPO overcame the
negative effects of trastuzumab and
enhanced the survival and proliferation
of HER2-positive breast cancer cells.
Strikingly, the effects were confirmed inovember 16, 2010 ª2010 Elsevier Inc. 401
Figure 1. Trastuzumab and EPO Interact Unfavorably in HER2-Positive Breast Cancer
Trastuzumab binds the extracellular domain of HER2, thereby inhibiting HER2/HER3 complexes and
downstream signaling cascades (Src, PI3K and MEK) that are constitutively active in tumor cells overex-
pressing HER2. EPO is a hematopoietic cytokine that supports survival, proliferation, and differentiation of
erythroid progenitors (erythroid colony forming units CFUe) in the bone marrow. The EpoR is expressed
not only in the hematopoietic compartment but also on cells of some cancer tissues. EPO binding to
EpoR stimulates numerous pathways (Stat5, PI3K, and MEK) via activation of the receptor-associated
JAK2 kinase.
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in which the growth of HER2-positive
tumors was totally suppressed by treat-
ment with trastuzumab but rescued
by the simultaneous administration of
rHuEPO to the mice.
The mechanism underlying the antago-
nism between trastuzumab and rHuEPO
on tumor cell proliferation and survival is
likely due to the overlap in signal trans-
duction components activated down-
stream of HER2 and EpoR. Although
the ligand receptor systems are clearly
distinct, a small number of molecular
pathways are commonly activated by
both receptors. The authors focused on
the PI3K/Akt and Erk pathways as well
as Src kinase, each of which is affected
by both receptor systems. Trastuzumab
disrupts the HER2/HER3/PI3K complex
(Junttila et al., 2009), which has an impor-
tant role in its anticancer activity. Further-
more, it has been observed that at least
in some models, trastuzumab reduces
the HER2/Src association and induces
PTEN activation (Nagata et al., 2004).
Treatment of HER2-positive tumor cells
with rHuEPO stimulated the association
between HER2 and Src and increased402 Cancer Cell 18, November 16, 2010 ª20activity of PI3K/Akt and Erk, thereby
counteracting the effects of trastuzumab
(Figure 1).
To test the clinical relevance, Liang and
colleagues retrospectively examined
HER2-positive metastatic breast cancer
patients treated with trastuzumab, with
or without chemotherapy, for progres-
sion- free survival and overall-survival
intervals; one group of patients had been
treated concurrently with rHuEPO and
trastuzumab. Their analysis suggested
that in this small cohort of patients, con-
current rHuEPO might have contributed
to trastuzumab resistance. Importantly,
they analyzed PTEN levels and PIK3CA
mutation status in eight samples and
found that four of the trastuzumab-resis-
tant tumors were PTEN positive and
PIK3CA wild type. Thus, not all trastuzu-
mab-resistant patients have mutations
that have been predicted to confer
insensitivity to the antibody, suggesting
that rHuEPO might have influenced
trastuzumab response via its ability to
activate specific pathways like Src or
PI3K/Akt.
ErbB-targeted drugs have had impor-
tant clinical activity (Baselga and Swain,10 Elsevier Inc.2009); however, further advances are
necessary, since many patients who are
initially responsive to ErbB receptor-
targeted therapies become resistant.
Although multiple mechanisms respon-
sible for drug resistance have been sug-
gested, unfavorable interactions between
targeted drugs might be contributors that,
up to now, have been underestimated.
In addition to monitoring breast tumors
for HER2 expression, testing for EpoR
expression could help in clinical decisions
and facilitate the choice of optimal drug
combinations. The improved prediction
of combined drug effects will be beneficial
not only for the patients, but will also
prevent the use of costly anticancer
agents that have unfavorable interactions.ACKNOWLEDGMENTS
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